The Innovative Molecular Analysis Technologies (IMAT) program was established to support the development, technical maturation, and dissemination of novel and potentially transformative next-generation technologies through an approach of balanced but targeted innovation. In support of its mission, the IMAT program utilizes a variety of investigator-initiated research project grant mechanisms while retaining a strong commitment to diversity and to the training of scientists and clinicians in cross-cutting, research-enabling disciplines.
The NCI is very pleased to announce that the IMAT program has approved reissuance for funding opportunity announcements through calendar year (CY) 2015.
Please use the links below for examples of past funding opportunities. New funding opportunities will be linked once posted.
Funding opportunities in technology development are intended to support the inception, maturation, and subsequent dissemination of technically innovative and potentially transformative emerging technologies. These opportunities exist in parallel with various educational and training programs aimed at the recruitment, retention, and promotion of a diverse pool of talent in areas of emerging technology.
FDA holding workshop on NGS.
The Food and Drug Administration (FDA) is announcing a free public Workshop to be held on the NIH campus on Feb 20, 2015 entitled: “Optimizing FDA’s Regulatory Oversight of Next Generation Sequencing Diagnostic Tests.” The purpose of this workshop is to discuss and receive feedback from the community on FDA’s regulatory approach to diagnostic tests for human genetics or genomics using Next Generation Sequencing (NGS) technology. The meeting will be webcast for those not able to attend in person. Please register here if you wish to attend.
New 2015 IMAT RFAs now open!
Cancer Detection, Diagnosis, and Treatment Technologies for Global Health (UH2/UH3)
The NCI has issued a new solicitation to support the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost devices or assays that are clinically comparable to currently used technologies for imaging, in vitro detection/diagnosis, or treatment of cancers in humans living in LMICs. more +
IMAT support leads to new commercial glycan tagging kit from Cambridge Isotope Laboratories.
Congratulations to the Muddiman group (NCSU) for commercial launch of their INLIGHTTM glycan tagging kit, an important new tool for enabling mass spectrometry-based glycomics research. more +
The Innovative Molecular Analysis Technologies Development for Cancer Research and Clinical Care (IMAT-SBIR, PAR-13-327) funding opportunity provides to small businesses conducting research towards the commercial development of emerging molecular and/or cellular analytical technologies intended for cancer detection and/or characterization. more +